Zelniker TA., Morrow DA., Mosenzon O, et al. - Researchers assumed that baseline NT‐proBNP and hsTnT levels would help distinguish patients who are at higher baseline risk and they further reported the treatment impacts of dapagliflozin in patients according to their baseline NT‐proBNP and hsTnT levels. This was a prespecified biomarker study from DECLARE­TIMI 58, a randomized, double‐blind, placebo‐controlled CV outcomes trial of dapagliflozin to assess baseline NT‐proBNP and hsTnT levels in the TIMI Clinical Trials Laboratory in 14,565 individuals. The data exhibited that individuals with T2DM and higher NT‐proBNP or hsTnT levels are at elevated risk of cardiovascular death or hospitalization for heart failure (CV death/HHF). This study’s findings revealed that dapagliflozin decreased the relative risk of CV death/HHF irrespective of NT‐proBNP and hsTnT levels, with greater absolute risk reductions seen in individuals with higher baseline biomarker levels.